Detalhe da pesquisa
1.
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Nature;
559(7712): 125-129, 2018 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29950729
2.
A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations.
Mol Cell;
63(4): 711-719, 2016 08 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27477909
3.
Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells.
Blood;
129(13): 1779-1790, 2017 Mar 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28077417
4.
TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS.
EMBO J;
32(5): 645-55, 2013 Mar 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23353889
5.
Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights.
JCO Precis Oncol;
8: e2300234, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38295318
6.
CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype Specific Vulnerability in IDH2- and TET2-Mutant Cells.
Cancer Discov;
2024 May 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38819218
7.
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.
Haematologica;
98(6): 908-12, 2013 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23349305
8.
An MDM2 degrader for treatment of acute leukemias.
Leukemia;
37(2): 370-378, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36309559
9.
Murine Modeling of Myeloproliferative Neoplasms.
Hematol Oncol Clin North Am;
35(2): 253-265, 2021 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33641867
10.
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies.
Hemasphere;
5(4): e549, 2021 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33718803
11.
Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML.
Cancer Discov;
10(12): 1934-1949, 2020 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32938585
12.
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
Cancer Discov;
9(6): 756-777, 2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30862724
13.
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Cancer Discov;
9(7): 872-889, 2019 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31076479
14.
Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.
Cancer Cell;
33(1): 44-59.e8, 2018 01 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29275866
15.
Correction: An MDM2 degrader for treatment of acute leukemias.
Leukemia;
37(8): 1764-1765, 2023 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37391487
16.
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
J Clin Invest;
128(2): 789-804, 2018 02 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29355841
17.
TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.
Cancer Discov;
8(12): 1632-1653, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30274972
18.
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
Cancer Discov;
8(12): 1540-1547, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30355724
19.
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.
Cancer Discov;
7(5): 494-505, 2017 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28193779
20.
Platelet-derived growth factor (PDGF) and glial tumorigenesis.
Cancer Lett;
232(2): 139-47, 2006 Feb 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16139423